Advertisement

Intensive Care Medicine

, Volume 40, Issue 6, pp 888–890 | Cite as

Understanding paracetamol-induced liver failure

  • Fin Stolze LarsenEmail author
  • Julia Wendon
Understanding the Disease

Paracetamol (N-acetyl-p-aminophenol) is among the most widely used over-the-counter antipyretic and analgesic drugs. Paracetamol is generally considered to be safe at recommended therapeutic doses but concerns accumulate worldwide, as it has been recognized as a frequent cause of acute liver failure (ALF).

Toxicity profile

Paracetamol is absorbed from the small intestine with a peak serum concentration within 1–2 h for tablet preparations and within 30 min for liquid preparations. Measured levels do normally not exceed 130 μmol/L but are dependent upon effective gastric emptying. The mechanism of action is not completely understood but is assumed to be related to inhibition of cyclooxygenase and modulation of the endogenous cannabinoid system. Following absorption paracetamol is mainly metabolized in the liver into water-soluble substances by glucuronidation and sulphation that are then excreted in the urine. A smaller fraction (10–15 %) is eliminated by N-hydroxylation by cytochrome...

Keywords

Paracetamol Hepatic Encephalopathy Lactic Acidosis Acute Liver Failure Bioactivation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

ALF

Acute liver failure

NAC

N-Acetylcysteine

NAPQI

N-Acetyl-p-benzoquinone imine

References

  1. 1.
    Prescott LF (1979) Paracetamol poisoning. Prevention of liver damage. Med Chir Dig 8:391–393PubMedGoogle Scholar
  2. 2.
    Khalid SK, Lane J, Navarro V, Garcia-Tsao G (2009) Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis. Clin Gastroenterol Hepatol 7(9):994–999PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Prescott LF (1996) Hepatotoxicity. In: Prescott LF (ed) Paracetamol (acetaminophen): a critical bibliographic review. Taylor & Francis, London, pp 285–351Google Scholar
  4. 4.
    Clemmesen JO, Kondrup J, Ott P (2000) Splanchnic and leg exchange of amino acids and ammonia in acute liver failure. Gastroenterology 118(6):1131–1139PubMedCrossRefGoogle Scholar
  5. 5.
    Cordoba J, Ventura-Cots M, Simón-Talero M, Amorós A, Pavesi M, Vilstrup H, Angeli P, Domenicali M, Ginés P, Bernardi M, Arroyo V, CANONIC Study Investigators of the EASL-CLIF Consortium (2014) Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol 60(2):275–281PubMedCrossRefGoogle Scholar
  6. 6.
    Bernal W, Wendon J (2013) Acute liver failure. N Engl J Med 369(26):2525–2534PubMedCrossRefGoogle Scholar
  7. 7.
    Schmidt LE, Larsen FS (2006) Prognostic implications of hyperlactatemia, multiple organ failure, and systemic inflammatory response syndrome in patients with acetaminophen-induced acute liver failure. Crit Care Med 34(2):337–343PubMedCrossRefGoogle Scholar
  8. 8.
    Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P (1999) Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 29(3):648–653PubMedCrossRefGoogle Scholar
  9. 9.
    Shawcross DL, Wendon JA (2012) The neurological manifestations of acute liver failure. Neurochem Int 60(7):662–671PubMedCrossRefGoogle Scholar
  10. 10.
    Antoniades CG, Khamri W, Abeles RD, Taams LS, Triantafyllou E, Possamai LA, Bernsmeier C, Mitry RR, O’Brien A, Gilroy D, Goldin R, Heneghan M, Heaton N, Jassem W, Bernal W, Vergani D, Ma Y, Quaglia A, Wendon J, Thursz M (2013) Secretory leukocyte protease inhibitor: a pivotal mediator of anti-inflammatory responses in acetaminophen induced acute liver failure. Hepatology 59(4):1564–1576. doi: 10.1002/hep.26933 CrossRefGoogle Scholar
  11. 11.
    Stravitz RT, Lisman T, Luketic VA et al (2012) Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 56:129–136PubMedCrossRefGoogle Scholar
  12. 12.
    Simpson KJ, Bates CM, Henderson NC et al (2009) The utilization of liver transplantation in the management of acute liver failure: comparison between acetaminophen and non-acetaminophen etiologies. Liver Transpl 15:600–609PubMedCrossRefGoogle Scholar
  13. 13.
    Harrison PM, Keays R, Bray GP, Alexander GJ, Williams R (1990) Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of N-acetylcysteine. Lancet 335(8705):1572–1573PubMedCrossRefGoogle Scholar
  14. 14.
    Schmidt LE, Wang LP, Hansen BA, Larsen FS (2003) Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 9(3):290–297PubMedCrossRefGoogle Scholar
  15. 15.
    Saliba F, Camus C, Durand F, Mathurin P, Letierce A, Delafosse B, Barange K, Perrigault PF, Belnard M, Ichaï P, Samuel D (2013) Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med 159(8):522–531PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg and ESICM 2014

Authors and Affiliations

  1. 1.Department of Hepatology, RigshospitaletUniversity Hospital of CopenhagenCopenhagen ØDenmark
  2. 2.Institute of Liver StudiesKings College HospitalLondonUK

Personalised recommendations